Tafamidis ATTR denied due to quantity / dose limits by Aetna?

Aetna's specific coverage criteria for tafamidis attr are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Imposes Quantity Limits on Tafamidis — and How to Challenge Them

Quantity limit (QL) edits are automated restrictions on the amount of a drug covered per dispensing period. For tafamidis, a QL denial typically means the prescription as written exceeds the quantity Aetna's system expects based on its coverage policy interpretation of the FDA-approved dosing. This can occur even when the prescriber has written a quantity that is consistent with the label. QL denials are procedural rather than clinical in nature and are among the more straightforward denial types to resolve, either by resubmitting with a corrected quantity or by appealing with supporting label documentation.

## Your Federal Appeal Rights

• ACA §2719 External Review: Available after exhausting internal appeals, generally within approximately four months of the final denial notice. Confirm the exact window on your Explanation of Benefits.
• ERISA §503: Employer-plan members are entitled to the specific quantity limit and plan language behind the restriction, plus a full-and-fair review.
• Expedited Track: Request simultaneously if delay would jeopardize your health — decision typically required within 72 hours.

## Concrete Appeal Steps and Timeline

1. Ask Aetna exactly what quantity limit is in place and what quantity was submitted — the gap between these two numbers is the basis of the denial. 2. Review the FDA-approved prescribing information to confirm the labeled dosing frequency and supply period. 3. If the prescriber wrote a quantity consistent with the label and Aetna's limit is lower, file a Level 1 internal appeal attaching the relevant section of the FDA label. 4. Ask the prescriber's office whether resubmitting with an adjusted days' supply or quantity notation could resolve the edit without a full appeal. 5. If the quantity limit reflects a policy that is stricter than the label without clinical justification, escalate to external review after internal denial.

## Documentation to Gather

• FDA prescribing information: The dosing and administration section establishing the approved supply interval — attach this to any appeal.
• Prescription details: The exact quantity and days' supply as written, and what was submitted to Aetna.
• Prescriber letter: A brief note confirming the quantity is medically appropriate and consistent with the label for this patient's treatment plan.
• Diagnosis confirmation: Records establishing the ATTR-CM diagnosis, since some QL exceptions require re-verification of the underlying indication.

## Criteria-Mapping Structure

Your appeal should be concise: state the quantity prescribed, the quantity Aetna will cover, and cite the specific section of the FDA label showing the approved dosing. If Aetna's quantity limit is lower than what the label supports, that discrepancy is your primary argument. Keep the letter to one page with the label excerpt attached. For QL appeals, brevity and precision outperform length.